H1N1 (swine flu) Vaccination Market

The H1N1 Influenza A (2009) pandemic has affected more than 0.4 million people in 180 countries across the globe. The alphabets H and N designate the proteins Hemagglutinin and Neuraminidase present on the surface area of the virus. The flu first began in Mexico in March 2009, then affected the U.S., after which it spread across the globe. The H1N1/09 virus has genetic elements originating from avian, swine, and human sources, making it far more fatal than the 1918 H1N1 (Spanish Flu) outbreak.

Curative drugs such as Tamiflu were introduced in the initial phase of the H1N1 pandemic. The latter phase would require drugs facilitating prevention rather than the cure. This market research report forecasts the H1N1 vaccine market for disease prevention in the unaffected population. The initial lot of vaccines will be egg-based and cell-based and first administered to priority groups such as pregnant women, chronic disease patients, and children above 6 months of age.

The global H1N1 influenza vaccine market is expected to be $676 million in 2009. The market is expected to show a high CAGR of 222.4% from 2009 to 2011; but as most of the global population is expected to be immunized by the end of 2011, a more moderate growth is expected in the future. The overall H1N1 vaccines market is classified into the intramuscular and intranasal vaccines submarkets, of which the former holds the major share.

Governmental involvement and the increased awareness about the pandemic is driving the growth of the H1N1 vaccines market; thus encouraging market players to gain a better understanding of the market dynamics, technological innovations, product pricing, marketing, and regulatory framework. The first movers are GlaxoSmithKline (GSK), Novartis, Commonwealth Serum Laboratories (CSL), Medimmune, Baxter, Sinovac, and Sanofi Pastuer. These companies have received approvals from various governments, including those of the U.S., the U.K., France, China, Denmark, and Australia. The U.S.-based Medimmune is currently the only manufacturer of the intranasal vaccine.

What makes our reports unique?

1. We provide the longest market segmentation chain in the industry with our three-level market breakdown and our analysis of minimum 40 collectively exhaustive and mutually exclusive micro markets.
2. We provide 10% customization to ensure that our clients find the specific market intelligence they need.
3. Each report is about 150 pages, featuring 30+ market data tables, 30+ company profiles, and an analysis of 200 patents.
4. No single report by any other publisher provides market data for all market segments (i.e. products, services, applications, ingredients, and technology) covering the four geographies of North America, Europe, Asia Pacific, and ROW.
5. 15 pages of high level analysis identifying opportunities, best practices, entry strategies, benchmarking strategies, market positioning, product positioning, and competitive positioning.

Key questions answered

1. Which are the high-growth segments and how is the market segmented in terms of applications, products, services, ingredients, technologies, stakeholders?
2. What are market estimates and forecasts; which markets are doing well and which are not?
3. Where are the gaps and opportunities; what factors are driving market growth?
4. Which are the key playing fields and winning-edge imperatives?
5. What is the competitive landscape; who are the main players in each segment; what are their strategic directives, operational strengths, key selling products, and product pipelines? Who is doing what?

Powerful Research and analysis

The analysts working with MarketsandMarkets come from renowned publishers and market research firms globally, adding their expertise and domain understanding. We get the facts from over 22,000 news and information sources, a huge database of key industry participants and draw on our relationships with more than 900 market research companies.

H1N1 Influenza A (2009) is the first pandemic influenza of 21^st century affecting more than more than four lac people in more than 180 countries across the globe in 2009.  The flu broke in Mexico in the month of March and then affected U.S. and after that it spread across the globe.  H1N1 (2009) influenza have a mutation of pig, bird and humans which has made it more dangerous and fatal compared to previous occurrence of H1N1 (1918).

The pandemic outbreak of the influenza opened the gates for the drugs such as Tamiflu in the initial phase for the curing of the disease but the following phase will see a shift from curing to prevention.  Thus, arise the requirement for the vaccine for the treatment of H1N1. H1N1 vaccine market is the forecast for the upcoming vaccines for the prevention of the disease among the unaffected population. The vaccines market is classified for the intramuscular vaccines and intranasal vaccines. Intramuscular will cater 80-85% of market revenues and the remaining will be tapped by the intranasal vaccines. The initial lot of vaccines will be of egg based and cell based manufacturing. The market forecast is from late 2009 as the first lot of doses are expected to be rolled out in the first week of October 2009.

The first movers of the in the vaccines market are Glaxo Smith Kline (GSK), Novartis, CSL, Medimmune, Baxter, Sinovac and Sanofi Pastuer. Medimmune is the only producer of the intranasal vaccine whereas other companies are expected to come out with intramuscular vaccines. The companies have got approvals for their first lots from the governments of the various countries such as U.S., U.K., France, China, Denmark and Australia. The involvement of government bodies, increased awareness about prevention and pandemic situation of the influenza is driving the market for the vaccines.

Due to intensive ongoing research and technology introduction, the market players are compelled to understand the market dynamics, innovations,  pricing, products, marketing and regulatory framework of the market.

The global H1N1 Influenza vaccine market is estimated to be of 676 million in 2009 with first lot of doses being commercialized on 30^th September’ 2009. The market will see a high CAGR for the next two years i.e. the market is expected to be at $7.03 billion in 2011 with a CAGR of 222.4% from 2009 to 2011.